Core B - The developmental component of the UCSD CFAR is designed to facilitate and encourage new investigators and new ideas in HIV/AIDS research. The intent is to optimize opportunities for productive research by providing immediate financial support in association with resource support provided by the Core facilities. Three categories of developmental grants will be supported, although the number and type of these categories are flexible: (1) foster junior investigators;(2) support newly-recruited faculty involved with HIV-related research;and (3) respond rapidly to evolving research opportunities. Requests for submission of developmental grants are advertised through the Administrative Core twice a year for funding in January and July. Faculty at all four CFAR member institutions are eligible to apply. The submissions are evaluated by an expert review committee and additional ad hoc reviewers who are experts in the pertinent fields as needed. Scientific merit is the primary criterion for making the awards;however, fostering the development of junior investigators is an important programmatic goal that is also considered in prioritization of awards. The maximum amount for the awards currently given is $50,000 for unfunded junior investigators and $30,000 for others. Grants to senior investigators must receive prior approval from the NIAID CFAR Program Office. As part of their award, investigators are required to provide documentation of publications and peer-reviewed funding that result from the developmental awards. They are also required to cite CFAR developmental funds in publications resulting from work supported by developmental grants. The Developmental Core also coordinates the NCI-funded pilot grants in HIV malignancies, in partnership with the UCSD Moores Cancer Center. The CFAR and Cancer Center issue joint requests for applications and conduct joint reviews. The Developmental Core coordinates the CFAR portion of this collaboration. The Developmental Core has an active and effective mentorship program. With the growth of the CFAR, anticipate a greater number of innovative and timely projects will be funded, attracting new members and affiliates who can advance HIV and AIDS research.

Public Health Relevance

The CFAR Developmental Core provides critical funding for developmental projects, particularly to junior investigators. The funding and mentorship offered through the Developmental Core generate innovative research and pilot data for investigators to publish and to use to generate larger grant applications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-20
Application #
8648956
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
20
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Garfein, Richard S; Liu, Lin; Cuevas-Mota, Jazmine et al. (2018) Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis 24:1806-1815
Heldt, Sven; Prattes, Juergen; Eigl, Susanne et al. (2018) Diagnosis of invasive aspergillosis in hematological malignancy patients: Performance of cytokines, Asp LFD, and Aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect 77:235-241
Jenks, Jeffrey Daniel; Hoenigl, Martin (2018) CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. J Lab Precis Med 3:
Canan, Chelsea E; Chander, Geetanjali; Monroe, Anne K et al. (2018) High-Risk Prescription Opioid Use Among People Living With HIV. J Acquir Immune Defic Syndr 78:283-290
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Gianella, Sara; Marconi, Vincent C; Berzins, Baiba et al. (2018) Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr 79:e112-e114
Innes, Steve; Patel, Kunjal (2018) Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings. Curr Opin HIV AIDS 13:187-195
Morales, Mario; Rafful, Claudia; Gaines, Tommi L et al. (2018) Factors associated with extrajudicial arrest for syringe possession: results of a department-wide survey of municipal police in Tijuana, Mexico. BMC Int Health Hum Rights 18:36
Rhodes, Tim (2018) The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential. Soc Sci Med 201:71-79

Showing the most recent 10 out of 921 publications